van Ryn J - Search Results

1

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.

Clemens A, van Ryn J, Sennewald R, Yamamura N, Stangier J, Feuring M, Härtter S. Clemens A, et al. Among authors: van ryn j. Eur J Clin Pharmacol. 2012 May;68(5):607-16. doi: 10.1007/s00228-011-1205-2. Epub 2012 Jan 18. Eur J Clin Pharmacol. 2012. PMID: 22252796 Free PMC article. Clinical Trial.

2

Interpretation of point-of-care INR results in patients treated with dabigatran.

van Ryn J, Baruch L, Clemens A. van Ryn J, et al. Am J Med. 2012 Apr;125(4):417-20. doi: 10.1016/j.amjmed.2011.10.017. Epub 2012 Feb 3. Am J Med. 2012. PMID: 22306274

3

The discovery of dabigatran etexilate for the treatment of venous thrombosis.

Feuring M, van Ryn J. Feuring M, et al. Among authors: van ryn j. Expert Opin Drug Discov. 2016 Jul;11(7):717-31. doi: 10.1080/17460441.2016.1188077. Epub 2016 May 30. Expert Opin Drug Discov. 2016. PMID: 27159158 Review.

4

Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.

Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J. Reilly PA, et al. Among authors: van ryn j. Am J Emerg Med. 2016 Nov;34(11S):26-32. doi: 10.1016/j.ajem.2016.09.050. Epub 2016 Sep 28. Am J Emerg Med. 2016. PMID: 27707528 Free article. Review.

5

Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.

Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Eisert WG, et al. Among authors: van ryn j. Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1885-9. doi: 10.1161/ATVBAHA.110.203604. Epub 2010 Jul 29. Arterioscler Thromb Vasc Biol. 2010. PMID: 20671233 Review.

6

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. van Ryn J, et al. Thromb Haemost. 2010 Jun;103(6):1116-27. doi: 10.1160/TH09-11-0758. Epub 2010 Mar 29. Thromb Haemost. 2010. PMID: 20352166 Review.

7

The discovery of dabigatran etexilate.

van Ryn J, Goss A, Hauel N, Wienen W, Priepke H, Nar H, Clemens A. van Ryn J, et al. Front Pharmacol. 2013 Feb 12;4:12. doi: 10.3389/fphar.2013.00012. eCollection 2013. Front Pharmacol. 2013. PMID: 23408233 Free PMC article.

8

Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.

van Ryn J, Schurer J, Kink-Eiband M, Clemens A. van Ryn J, et al. Anesthesiology. 2014 Jun;120(6):1429-40. doi: 10.1097/ALN.0000000000000255. Anesthesiology. 2014. PMID: 24714118 Free article.

9

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.

Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, Lang B, Ramael S, Reilly P. Glund S, et al. Among authors: van ryn j. Thromb Haemost. 2015 May;113(5):943-51. doi: 10.1160/TH14-12-1080. Epub 2015 Mar 19. Thromb Haemost. 2015. PMID: 25789661 Clinical Trial.

10

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J. Glund S, et al. Among authors: van ryn j. Lancet. 2015 Aug 15;386(9994):680-90. doi: 10.1016/S0140-6736(15)60732-2. Epub 2015 Jun 15. Lancet. 2015. PMID: 26088268 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

80 results

Search Page

Filters